GAMMA Investing’s Prime Medicine PRME Stock Holding History

GAMMA Investing’s Portfolio PRME Stock Details PRME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.33K	Buy	761 +175	+30%	+$581	﹤0.01%	3905
2026 Q2	$2.16K	Sell	586 -61	-9%	-$203	﹤0.01%	3718
2026 Q1	$2.25K	Buy	647 +536	+483%	+$2.04K	﹤0.01%	3637
2025 Q4	$385	Buy	+111	New	+$494	﹤0.01%	3939
2024 Q4	–	Sell	-654	Closed	-$2.53K	–	3816
2024 Q3	$2.53K	Buy	654 +422	+182%	+$1.96K	﹤0.01%	2990
2024 Q2	$1.19K	Buy	+232	New	+$1.41K	﹤0.01%	3019
2024 Q1	–	Sell	-118	Closed	-$749	–	3360
2023 Q4	$749	Buy	+118	New	+$909	﹤0.01%	2874

Other funds holding PRME

GAA

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

FFO

Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return

GAMMA Investing's PRME Position: Q3 2026 in Review

GAMMA Investing increased its Prime Medicine (PRME) stake by 30% in Q3 2026, buying an estimated $581 and bringing the position to 761 shares worth $2.33K. The position accounts for ﹤0.01% of the portfolio, ranked #3905.

GAMMA Investing first reported a position in PRME in Q4 2023 and has held it in 7 quarters since. The position peaked at $2.53K in Q3 2024. 4 funds tracked by Wall St. Rank hold PRME as of Q3 2026.

GAMMA Investing held 761 shares of Prime Medicine worth $2.33K as of Q3 2026.
GAMMA Investing bought 175 Prime Medicine shares in Q3 2026, an estimated $581.
Prime Medicine made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3905 holding.
GAMMA Investing first reported a position in Prime Medicine in Q4 2023 and has held it in 7 quarters since.
GAMMA Investing's Prime Medicine position peaked at $2.53K in Q3 2024.
4 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.